Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Studie for å evaluere effektiviteten, sikkerheten og toleransen til IMU-838 hos pasienter med residiverende multippel sklerose (ENSURE-1)

28. september 2026 oppdatert av: Immunic AG

En multisenter, randomisert, dobbeltblindet fase 3-studie for å evaluere effektiviteten, sikkerheten og toleransen til IMU-838 versus placebo hos voksne med residiverende multippel sklerose (ENSURE-1)

Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 versus Placebo in Adults with Relapsing Multiple Sclerosis (ENSURE-1)

Studieoversikt

Status

Aktiv, ikke rekrutterende

Detaljert beskrivelse

This study will be a multicenter, randomized, double-blind, placebo-controlled study with a blinded Main Treatment Period (MT) and an Open Label Period (OLE) to evaluate the efficacy, safety, and tolerability of IMU-838 in adult patients with RMS. The study will consist of the following periods:

Screening Period: Approximately 28 days Main Treatment Period: Up to 72 weeks (approximately 15 months) Open Label Extension Period: Up to approximately 8 years

Studietype

Intervensjonell

Registrering (Faktiske)

1121

Fase

  • Fase 3

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

      • Tirana, Albania, 1005
        • Klinika Mjekesore Nuova, Neurology Clinic
      • Tirana, Albania
        • Hygeia Hospital Tirana
      • Algiers, Algerie, 16000
        • University Hospital Center Mustapha Pacha, Algiers
      • Annaba, Algerie, 23000
        • University Hospital Center Ibn Sina, Annaba
      • Oran, Algerie, 31000
        • University Hospital Center of Oran
      • Blagoevgrad, Bulgaria, 2700
        • MHAT Puls AD
      • Burgas, Bulgaria, 8000
        • MHAT "Heart and Brain", EAD
      • Pleven, Bulgaria, 5800
        • MC Exacta Medica OOD
      • Pleven, Bulgaria, 5800
        • MHAT Avis Medica
      • Pleven, Bulgaria, 5800
        • UMHAT Dr.Georgi Stranski EAD
      • Pleven, Bulgaria
        • Heart and Brain University Hospital
      • Pleven, Bulgaria
        • MC Vita 1
      • Plovdiv, Bulgaria, 4002
        • UMHAT Sveti Georgi
      • Plovdiv, Bulgaria, 4001
        • UMHAT "Kaspela"EOOD
      • Plovdiv, Bulgaria, 4002
        • UMHAT "Pulmed" Ltd
      • Rousse, Bulgaria
        • UMHAT "Medica Ruse"
      • Sofia, Bulgaria, 1431
        • UMHAT "Alexandrovska"
      • Sofia, Bulgaria, 1431
        • UMHAT "Alexandrovska" EAD
      • Sofia, Bulgaria
        • Military Medical Academy
      • Sofia, Bulgaria, 1606
        • Military Medical Academy MHAT
      • Sofia, Bulgaria, 1000
        • CCB Medical Institute Ministry of Interior
      • Sofia, Bulgaria, 1000
        • Diagnostic and Consultative Center Neoclinic
      • Sofia, Bulgaria, 1000
        • UMHAT "Sveti Ivan Rilski" EAD
      • Sofia, Bulgaria, 1113
        • MHATNP "Sveti Naum", EAD
      • Sofia, Bulgaria, 1113
        • MHATNPsy Sveti Naum EAD
      • Sofia, Bulgaria, 1618
        • MHAT "Sveta Sofia" EOOD
      • Sofia, Bulgaria
        • UMHAT"Tsaritsa Yoanna -ISUL
      • Sofia, Bulgaria
        • UMHATEM N.Pirogov
      • Varna, Bulgaria
        • UMHAT "Sveta Marina" EAD, First Clinic of Neurological Diseases
    • Arizona
      • Phoenix, Arizona, Forente stater, 85004
        • Xenoscience, Inc., 21st Century Neurology
    • California
      • West Hollywood, California, Forente stater, 90048
        • Regina Berkovich MD, PhD Inc. MS Neurology
    • Florida
      • Bradenton, Florida, Forente stater, 34205
        • Bradenton Research Center
      • Naples, Florida, Forente stater, 34105
        • Collier Neurologic Specialists
      • Ormond Beach, Florida, Forente stater, 32174
        • Neurology Associates of Ormond Beach
    • Illinois
      • Northbrook, Illinois, Forente stater, 60062
        • Consultants in Neurology, Ltd
      • Tbilisi, Georgia
        • LTD Aversi Clinic
      • Tbilisi, Georgia, 0141
        • 1st Uni Clinic of Tbilisi LEPL
      • Tbilisi, Georgia
        • Eristavi Experimental Center
      • Tbilisi, Georgia
        • J.S.C. Curatio Clinic
      • Tbilisi, Georgia
        • Khechinashvili University Hospital
      • Tbilisi, Georgia
        • LTD New Hospitals
      • Tbilisi, Georgia
        • MediClub Georgia LLC
      • Tbilisi, Georgia
        • Sarajishvili Neurology Institute
      • Tbilisi, Georgia
        • JSC "Jerarsi"
      • Tbilisi, Georgia
        • Pineo Medical Ecosystem LTD
      • Bangalore, India, 560092
        • Medstar Speciality Hospital
      • Mangalore, India, 575002
        • Mallikatte, Kadri
      • Nagpur, India
        • Jasleen Hospital
      • New Delhi, India, 110060
        • Sir Ganga Ram Hospital
      • Pune, India, 411001
        • Ruby Hospital
      • Shimla, India, 171006
        • Atal Institute of Medical Super Specialities (AIMSS)
      • Varanasi, India, 221005
        • Institute of Medical Sciences Banaras Hindu University,IMS BHU Varanasi
      • Amman, Jordan, 11942
        • Jordan University Hospital
      • Amman, Jordan, 11196
        • Istiklal Hospital
      • Amman, Jordan
        • TSH Advanced Clinical Center
      • Irbid, Jordan
        • Irbid Speciality Hospital
      • Beirut, Libanon
        • Hotel Dieu de France Hospital
      • Hamra, Libanon, 1107-2020
        • AUB Medical Center
      • Kaunas, Litauen, 50161
        • Lietuvos Sveikatos Mokslu Universitetas - Kauno Klinikos
      • Culiacán, Mexico, 80020
        • Neurociencias Estudios Clínicos S.C
      • Guadalajara, Mexico, 44670
        • Instituto Jalisciense de Metabolismo, SC
      • Mexico City, Mexico, 14050
        • Unidad de Investigación en Salud de Chihuahua S.C.
      • Mexico City, Mexico
        • Clinstile SA de CV
      • Mexico City, Mexico, 03310
        • Grupo medico camino SC
      • Mexico City, Mexico, 06700
        • Consultorio Médico Expert Brain Clinic
      • Morelia, Mexico, 58000
        • Centro de Morelia
      • Veracruz, Mexico, 91900
        • Sociedad de Metabolismo y Corazon, S.C.
      • Veracruz, Mexico, 91900
        • Faicic de RL de CV
      • Chisinau, Moldova
        • Instititute of Emergency Medicine
      • Chisinau, Moldova
        • Medico-Sanitary Public Institution, Institute of Neurology and Neurosurgery "Diomid Gherman"
      • Chisinau, Moldova
        • The Diomid Gherman Institute of Neurology and Neurosurgery
      • Nikšić, Montenegro
        • General Hospital Niksic
      • Podgorica, Montenegro
        • Clinical Center of Montenegro
      • Skopje, Nord-Makedonia
        • Hospital "8 mi Septemvri"
      • Skopje, Nord-Makedonia
        • University Clinic of Neurology
      • Lublin, Polen, 20-064
        • NZOZ Neuromed M. i M. Nastaj Sp. P.
      • Barnaul, Russland, 656045
        • City Hospital #5, Barnaul
      • Barnaul, Russland, 656906
        • Profimed LLC
      • Bryansk, Russland, 241033
        • Bryansk Regional Hospital 1
      • Chelyabinsk, Russland, 454021
        • Regional Clinical Hospital 3
      • Krasnoyarsk, Russland, 660037
        • Federal Siberian Scientific and Clinical Centre of Federal Medical and Biological Agency
      • Kursk, Russland, 305007
        • Kursk Regional Clinical Hospital
      • Nizhny Novgorod, Russland, 603076
        • Medis LLC
      • Novosibirsk, Russland, 630004
        • Sibneiromed LLC
      • Novosibirsk, Russland, 630007
        • SDMCH SDMC of FMBA of Russia
      • Perm, Russland, 614045
        • Perm State Medical University n.a. Acad. E. A. Vagner
      • Samara, Russland, 443095
        • Samara regional clinical hospital n. a. V. L. Seredavin
      • Yekaterinburg, Russland, 620102
        • Sverdlovsk Regional Clinical Hospital #1
      • Münster, Tyskland, 48149
        • University Hospital Muenster, Institute Translational Neurology dept. Neurology
      • Chernihiv, Ukraina, 14029
        • Communal Non-Commercial Enterprise "Chernihiv Regional Hospital",Department of Neurology
      • Chernivtsi, Ukraina, 58023
        • Regional Municipal Non-commercial Enterprise "Chernivtsi Emergency Medical Hospital"
      • Chernivtsi, Ukraina
        • Chernihiv Regional Hospital
      • Ivano-Frankivsk, Ukraina, 76008
        • Regional Clinical Hospital
      • Ivano-Frankivsk, Ukraina, 76493
        • Neuro Global, LLC
      • Khmelnytskyi, Ukraina
        • Khmelnytsky regional hospital of war veterans
      • Kiev, Ukraina
        • Clinical Hospital #15 of the Podilskyi District of the Kyiv City
      • Kyiv, Ukraina, 3037
        • "Medbud"
      • Kyiv, Ukraina, 4212
        • SMART medical center
      • Kyiv, Ukraina
        • Kyiv City Hospital 4
      • Odesa, Ukraina
        • Odesa Regional Clinical Hospital, Department of Neurosurgery
      • Poltava, Ukraina
        • Medical and diagnostic center of a LLC "Medcontinent", neurology and rehabilitation center
      • Ternopil, Ukraina, 46027
        • Ternopil Psycho-Neuro Hospital
      • Uzhhorod, Ukraina
        • Regional Clinical Center for Neurosurgery and Neurology

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 55 år (Voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Male or female patient (age ≥18 to ≤55 years).

  • Patients with an established diagnosis of MS according to 2017 McDonald Criteria.

  • Patients with RMS comprising of relapsing remitting MS (RRMS) and active secondary progressive MS, both defined according to Lublin criteria 1996 and 2014.

  • Active disease as defined by Lublin 2014 evidenced prior to Screening by:

    1. At least 2 relapses in the last 24 months before randomization, or
    2. At least 1 relapse in the last 12 months before randomization, or
    3. A positive Gd+ MRI scan (brain and/or spine) in the last 12 months prior to randomization.
  • Willingness and ability to comply with the protocol.

  • Written informed consent given prior to any study-related procedure.

Exclusion Criteria:

  • Patients with non-active secondary progressive MS and primary progressive MS.
  • Any disease other than MS that may better explain the signs and symptoms, including history of complete transverse myelitis.
  • Clinical signs or presence of laboratory findings suggestive for neuromyelitis optica (NMO) spectrum disorders or myelin oligodendrocyte glycoprotein (MOG)-IgG-associated encephalomyelitis
  • Any active and uncontrolled coexisting autoimmune disease, other than MS (except for type 1 diabetes mellitus and inflammatory bowel disease)
  • Use of experimental/investigational drug (with the exception ofCOVID-19 vaccines approved by emergency use authorization) and/or participation in drug clinical studies within 6 months prior to Screening
  • Previous or current use of MS treatments lifelong, or within a pre-specified time period.
  • Use of the pre-specified concomitant medications.
  • Clinically significantly abnormal and pre-specified lab values.
  • History of chronic systemic infections within 6 months before the date of informed consent.
  • Diagnosis or suspected liver function impairment, which may cause fluctuating liver function tests during this study.
  • Known history of nephrolithiasis or underlying condition with a strong association of nephrolithiasis.
  • History or clinical diagnosis of gout.
  • History or presence of any major medical or psychiatric illness
  • Substantial medical condition that could create undue risk to the patient, could affect adherence with the study protocol or could undesirably affect study outcomes

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Firemannsrom

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: IMU-838

IMU-838 (vidofludimus calcium), a small molecule inhibitor of DHODH.

Formulation:

Tablets with 15 or 30 mg IMU-838 for once daily oral intake in the morning.

Patients are randomized to IMU-838 or placebo in ratio 1:1

Andre navn:
  • vidofludimus kalsium
Placebo komparator: Placebo

Matching placebo, as described for the test product, identical number of tablets as given for IMU-838.

Patients are randomized to IMU-838 or placebo in ratio 1:1

Andre navn:
  • Placebo-matchende vidofludimus kalsium

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
To evaluate efficacy of IMU-838 versus placebo regarding time to first relapse
Tidsramme: 72 weeks

Survival analysis of time to first relapse, occurred after the start of study treatment administration and before the end of the double-blind period, censored at a maximum of 72 weeks.

72 weeks

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Effect of IMU-838 versus placebo on volume of new T2 lesions
Tidsramme: 72 weeks

To evaluate the effect of IMU-838 versus placebo on volume of new T2 lesions. Mean difference between IMU-838- and placebo in changes of the volume of new MRI T2 lesions over 24-weeks of treatment in the double-blind period.

72 weeks
Effect of IMU-838 versus placebo on disability progression
Tidsramme: 72 weeks

To evaluate the effect of IMU-838 versus placebo on disability progression. Survival analysis of time to 12-week confirmed disability progression, as measured on Expanded Disability Status Scale during the double-blind period, censored at maximum 72-weeks.

72 weeks
Effect of IMU-838 versus placebo on cognitive performance
Tidsramme: 72 weeks

To evaluate the effect of IMU-838 versus placebo on cognitive performance. Survival analysis of time to confirmed clinically relevant changes on Symbol Digit Modalities Test during the double-blind period, censored at maximum 72-weeks.

72 weeks
Effect of IMU-838 versus placebo on whole brain atrophy
Tidsramme: 72 weeks

To evaluate the effect of IMU-838 versus placebo on whole brain atrophy. Difference in the mean of the percentage change on the whole brain volume between IMU-838 and placebo during the 72-weeks double-blind period.

72 weeks
Safety of IMU-838 versus placebo
Tidsramme: 72 weeks

To evaluate safety and tolerability of IMU-838 versus placebo by assessing rates of Treatment Emergent Adverse Events, Adverse Events of Special Interest, Serious Adverse Events, changes in levels of pre-specified laboratory parameters, vital signs and ECG parameters and rates and reasons for study discontinuations.

72 weeks

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Etterforskere

  • Hovedetterforsker: Robert J. Fox, MD, Mellen Center for MS, Neurological Institute, Cleveland Clinic, Ohio

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

18. november 2021

Primær fullføring (Antatt)

1. november 2026

Studiet fullført (Antatt)

1. september 2033

Datoer for studieregistrering

Først innsendt

30. september 2021

Først innsendt som oppfylte QC-kriteriene

19. november 2021

Først lagt ut (Faktiske)

26. november 2021

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

1. oktober 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

28. september 2026

Sist bekreftet

1. september 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere